Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide ([@kfz168-B4]). Patients with heart failure (HF) comprise a growing percentage of the CVD population ([@kfz168-B4]). HF is instigated by both genetic, eg, inherited cardiomyopathy and acquired risk factors eg, coronary heart disease or hypertension ([@kfz168-B44]). Cardiotoxicity and HF can also be an unwanted consequence of treatment with a range of drugs in clinical usage ([@kfz168-B26]; [@kfz168-B28]; [@kfz168-B42]). There remains the need for both novel therapies to prevent and treat HF as well as improved ways to assess the cardiac safety liabilities of candidate drug therapies.

Cardiac contractility is a consequence of a precise series of events known as excitation-contraction coupling ([@kfz168-B12]). This highly orchestrated process links electrical excitation of the surface membrane (the action potential) and changes in the cytoplasmic calcium concentration (\[Ca^2+^\]~i~) to muscle contraction and relaxation ([@kfz168-B12]). Aberrant contractility is a hallmark of HF and of numerous drugs with cardiotoxic effects and contributes to symptoms including dyspnea, fatigue, arrhythmia, and ischemia ([@kfz168-B16]). Historically, contractility measurements have been performed using cardiac tissue isolated from patients or animals. The use of isolated tissues poses significant challenges, including limited availability and variability for the former, and species-to-species translation for the latter. These challenges have restricted the utility of these methods and highlight the need for novel models. For *in vitro* models to faithfully recapitulate this process they should demonstrate functional hallmarks of the electrical, calcium handling, and contractile machinery.

The recent development of robust cardiac differentiation protocols for human induced pluripotent stem cells (hiPSCs) has provided the potential for an unlimited supply of human derived cardiac cells from both healthy and diseased sources, but this potential has been limited by the observation that hiPSC-derived cardiomyocytes (hiPSC-CMs) typically retain a more fetal-like phenotype ([@kfz168-B11]; [@kfz168-B49]). This raises concerns about the predictability and translatability of results obtained *in vitro* to the settings of drug safety, discovery, and development.

In this study, the Biowire II platform was used to generate 3D engineered cardiac tissues (ECTs) from hiPSC-CMs and cardiac fibroblasts and to make nondestructive contractility measurements of the ECTs. We present data demonstrating that ECTs produced using this platform and subjected to long term electrical stimulation have adult-like contractile properties. In addition, we show that contractility in the ECTs can be modulated by a variety of agents known to effect essential intracellular signaling pathways present in the human myocardium. These data demonstrate the utility of the platform as a tool for discovery of novel therapies and testing of drug safety in preclinical development, using a human model of myocardial tissue.

MATERIALS AND METHODS
=====================

### 

#### Generation of ECTs

ECTs were generated in the Biowire II platform as described previously ([@kfz168-B52]). Briefly, 3D ECTs were formed in polystyrene microwells containing parallel poly(octamethylene maleate (anhydride) citrate) (POMaC) wires. Each ECT was comprised of 100 000 viable iCell Cardiomyocytes^*2*^ (Cellular Dynamics International, Madison, Wisconsin) and 10 000 human ventricular cardiac fibroblasts (Lonza, Allendale, New Jersey) in a collagen/Matrigel/fibrin gel. Following 7 days in culture, the hiPSC-CMs and cardiac fibroblasts self-organized into 3D ECTs and were suspended between the POMaC wires ([Figure 1A](#kfz168-F1){ref-type="fig"}). Custom chambers containing parallel carbon electrodes were used to provide electrical field stimulation using biphasic pulses of 2 ms duration, at twice the excitation threshold. Stimulation was started at 1 Hz and increased by 0.1 Hz increments daily to a maximum of 6 Hz. All ECTs used in this study were subjected to the same stimulation protocol for a minimum of 6 weeks. Compound effects on contractility were similar in tissues stimulated from 6 to 9 weeks.

![Engineered cardiac tissues (ECTs) generated in the Biowire II platform have adult-like contractile properties. A, A representative image of an ECT suspended in the Biowire II platform (*top left*). Twitch force is measured by acquiring a video of the contracting tissues under field stimulation and converting the pixel displacement of the poly(octamethylene maleate (anhydride) citrate) (POMaC) wire (*bottom left, red horizontal bars*) into a force measurement ([@kfz168-B52]). A time lapse of the POMaC displacement is shown on the *top right panel*. Once pixel movements are converted to force, parameters of contractility including maximal twitch amplitude or active force (*T*~peak~), time constants and rates of contraction and relaxation are derived (*bottom right*). B, ECTs stimulated in the Biowire II platform showed positive force-frequency relationship and (C) prominent postrest potentiation after 6 weeks of electrical stimulation. D, Summary of force-frequency relationship and postrest potentiation normalized to ECT cross-sectional area. (*n* = 6) ECTs. Data presented as mean ± SEM. \#*p* \< .05 using one-way ANOVA.](kfz168f1){#kfz168-F1}

#### Image-based contractility measurements

ECT contractility was measured by tracking the deflection of the POMaC wires as a function of time as previously described ([@kfz168-B52]). Stimulated ECTs were placed in a custom chamber containing parallel carbon electrodes to provide external field stimulation in an environmental chamber at 37°C and 5% CO~2~. ECTs were stimulated at twice the excitation threshold during acquisition. The POMaC wires were illuminated using 350 nm excitation. Videos were acquired at a rate of 100 frames per second using a Zyla 4.2 sCMOS camera (Andor, South Windsor, Connecticut) with a 470 nm emission filter using NIS-Elements Advanced Research software (Nikon Instruments Inc, Edgewood, New York). To measure contractile force, the videos were analyzed using custom software to track the location of the POMaC wire ([Figure 1A](#kfz168-F1){ref-type="fig"}). The pixel movements were converted to force as previously described ([@kfz168-B52]).

The force-frequency relationship (FFR) was determined by pacing ECTs at 1 Hz and increasing the stimulation frequency by 1 Hz every 30 s to a final frequency of 4 Hz. Following 4 Hz stimulation, the postrest potentiation was determined by turning off the external field stimulation for 10 s and recording the twitch transients after resuming field stimulation at 1 Hz. To determine the cross-sectional area of the tissue, ECTs were fixed in 10% neutral buffered formalin for 2 h followed by 3 washes in phosphate buffered saline. Tissue was cut halfway between the midsection of the tissue and the POMaC wire (red dotted line in [Figure 1A](#kfz168-F1){ref-type="fig"}). A photo of the transverse section was acquired, and the cross-sectional area was determined using ImageJ. Average tissue cross-sectional area was 0.066 ± 0.001 mm^2^ (*n* = 6 ECTs).

#### Compound testing

At the end of the electrical stimulation protocol, ECTs were assessed for automaticity (ie, spontaneous beat rate), the FFR (active force at 1 Hz through 4 Hz), and postrest potentiation. ECTs without spontaneous activity that exhibited a positive FFR and postrest potentiation were used for compound testing.

Tests were conducted in a 37°C, 5% CO~2~ environmental chamber under field stimulation at 1 Hz. Tissues were incubated for 30 min in the environmental chamber after which a baseline contractility video was acquired for 30 s. One-third of the tissue culture medium volume (6 ml total) was pipetted from the well containing the ECTs twice to equilibrate the ECTs to the shear stress induced by the procedure. A video of 30 s duration was acquired 10 min after the pipetting (baseline). The test article was added to the well to provide the desired final concentration and one-third of the media volume was pipetted twice to gently mix. The test article stock solutions were prepared in either dimethyl sulfoxide or water as appropriate, and serially diluted in medium. Following 10--30 min of incubation a video of 30 s duration was acquired. The same procedure was followed for all subsequent doses (lowest to highest) such that 1 ECT was incubated with all doses. Contractility videos were analyzed using a custom analysis software. The force at each dose was normalized by dividing the force values in the presence of compound by the baseline force values of the same tissue.

#### Statistics

Statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc, La Jolla, California). Data are presented as mean ± SEM. Results were considered statistically significant (\#) if *p* \< .05 using one-way ANOVA followed by a Tukey\'s post hoc multiple comparison test or where appropriate repeat measure one-way ANOVA followed by Dunnett's post hoc multiple comparison test. The replicate numbers are indicated in the figure captions. For EC~50~/IC~50~ calculation, the nonlinear fit function of GraphPad Prism (Sigmoidal with 3 parameters) was used to find the best fit for the data.

RESULTS
=======

### Cardiac ECTs Generated via the Biowire II Platform Have Adult-Like Contractile Properties

The functionality of the contractile machinery was assessed by measuring the frequency-dependent regulation of contractility, ie, the FFR. FFR is a property of the adult heart where a stepwise increase in force is observed when the frequency of stimulation is increased within a physiologically relevant range ([@kfz168-B8]). Prior to electrical stimulation ie, 1-week postseeding, the ECTs were spontaneously beating at approximately 1.5 Hz and had limited capture at 3 and 4 Hz impairing the ability to assess the FFR. After 7 weeks of culture (6 weeks of electrical stimulation), a positive FFR was observed ie, increased force of contraction with increasing stimulation frequencies ([Figs. 1B and 1D](#kfz168-F1){ref-type="fig"}).

We further investigated the contractile machinery of the ECTs by assessing postrest potentiation of force, an indicator of the capacity of the sarcoplasmic reticulum (SR) to store and release Ca^2+^. In large mammals and humans, short periods of cardiac rest give rise to an increased force of contraction of the first beats following restimulation. This results from to an increased uptake and subsequent release of Ca^2+^ from the SR ([@kfz168-B32]). Due to spontaneous beating, we could not assess postrest potentiation at 1-week postseeding. After 6 weeks of electrical stimulation, we observed a significant postrest potentiation of force following 10 s of rest ([Figs. 1C and 1D](#kfz168-F1){ref-type="fig"}).

In aggregate the data demonstrate that the ECTs manifest contractile parameters that approach that seen in adult human myocardium.

### ECTs Generated via Biowire II Display Positive Inotropic Responses to Drugs That Modulate Messenger 3′-5′-Cyclic Adenosine Monophosphate Production and Degradation

β-adrenergic signaling is an important physiological regulator of cardiac contractility ([@kfz168-B10]). It results in an increase in the production of the intracellular second messenger cyclic adenosine monophosphate (cAMP) and a positive inotropic response ([@kfz168-B6]). ECTs treated with the β-agonist isoproterenol showed a maximal 6.6 ± 0.8-fold increase in contractile force at a concentration of 10 nM with a half maximal effective concentration (EC~50~) of 0.5 nM ([Figure 2A](#kfz168-F2){ref-type="fig"}, time constants and rates of contraction and relaxation are summarized in [Supplemental Table 1](#sup1){ref-type="supplementary-material"}). Similarly, addition of dobutamine, a predominantly β~1~ agonist increased the maximal contractile force by 4.4 ± 0.6-fold at 360 nM with EC~50~ of 16 nM ([Figure 2B](#kfz168-F2){ref-type="fig"}).

![Engineered cardiac tissues (ECTs) respond to effectors of the cyclic adenosine monophosphate (cAMP) signaling pathway. A, Treatment with isoproterenol induced an increase in contractile force with EC~50~ of 0.5 nM (*n* = 12). B, Like isoproterenol, dobutamine induced an increase in contractile force with EC~50~ of 16 nM (*n* = 5). C, Milrinone, a phosphodiesterase-3 (PDE3) inhibitor also increased contractile force with EC~50~ of 1.6 µM (*n* = 6). D, Treatment with pituitary adenylate cyclase-activating peptide (PACAP27) induced an increase in contractile force with EC~50~ of 1.1 nM (*n* = 6). Data are presented as mean ± SEM.](kfz168f2){#kfz168-F2}

Further, we investigated the intracellular pathways involved in adrenergic signaling, using small molecule modulators that effect distinct signaling pathways. Degradation of cAMP is mediated by a cAMP-dependent enzyme, phosphodiesterase-3 (PDE3). We observed a maximal 4.3 ± 1.2-fold increase in the force of contraction when ECTs were treated with the PDE3 inhibitor milrinone at a concentration of 100 µM with an EC~50~ of 1.6 μM ([Figure 2C](#kfz168-F2){ref-type="fig"}, [Supplemental Table 1](#sup1){ref-type="supplementary-material"}).

Pituitary adenylate cyclase-activating polypeptide (PACAP27) is a 27-amino acid peptide that activates adenylyl cyclase via binding to its cognate G-protein-coupled receptor. We observed a maximal 3.4 ± 1.1-fold increase in force of contraction when ECTs were treated with 10 nM PACAP27 with an EC~50~ of 1.1 nM ([Figure 2D](#kfz168-F2){ref-type="fig"}, [Supplemental Table 1](#sup1){ref-type="supplementary-material"}).

### ECTs Have Functional L-Type Ca^2+^ Channels, SR, and Na^+^-Ca^2+^ Exchangers

The voltage-gated L-type Ca^2+^ Channels (LTCCs) are the primary mediators of Ca^2+^ influx into the cardiomyocyte, which is essential for initiation of cardiac excitation-contraction coupling ([@kfz168-B3]; [@kfz168-B5]). Treatment of ECTs with the LTCC blocker nifedipine completely inhibited contraction at a concentration of 1 μM with a half maximal inhibitory concentration (IC~50~) of 62 nM ([Figure 3A](#kfz168-F3){ref-type="fig"}, [Supplemental Table 2](#sup1){ref-type="supplementary-material"}), whereas treatment with the LTCC activator FPL 64176 induced a maximal 8.5 ± 0.6-fold increase in the force of contraction at a concentration of 10 µM with an EC~50~ of 502 nM ([Figure 3B](#kfz168-F3){ref-type="fig"}, [Supplemental Table 2](#sup1){ref-type="supplementary-material"}).

![Engineered cardiac tissues (ECTs) respond to calcium handling effectors. A, Treatment with nifedipine decreased contractile force with IC~50~ of 62 nM (*n* = 6). B, Treatment with FPL64176 induced a robust increase in contractile force with EC~50~ of 502 nM (*n* = 4). C, Treatment with digoxin induced a robust increase in contractile force at concentrations below 1 µM (*n* = 9). Higher concentrations of digoxin showed toxic effects with no contractility observed at doses higher than 10 µM. To calculate the EC~50~ for the positive inotropic effects of digoxin, concentration values above 1 µM where not included in the curve fit. D, Thapsigargin completely abolished contractile force at concentrations above 1 µM (IC~50~ = 165 nM, *n* = 6). Data are presented as mean ± SEM.](kfz168f3){#kfz168-F3}

The Na^+^-Ca^2+^ exchanger (NCX) is the primary means by which cardiomyocytes regulate intracellular Ca^2+^ and hence a critical modulator of excitation-contraction coupling. To assess the functionality of the NCX in this model we treated ECTs with digoxin. Digoxin is a cardiac glycoside, a class of compounds that directly inhibits the Na^+^/K^+^ ATPase and requires a functional NCX for its inotropic effect ([@kfz168-B1]; [@kfz168-B30]). The inhibition of the Na^+^/K^+^ ATPase results in increased intracellular Na^+^ accumulation, which reduces the electrochemical drive for Ca^2+^ efflux through NCX. In this setting excess intracellular Ca^2+^ is primarily removed from the cytosol by the sarco/endoplasmic reticulum Ca^2+^-ATPase (SERCA), which loads the SR with Ca^2+^ leading to an increase in cardiac contractility ([@kfz168-B29]). Treatment of ECTs with digoxin induced a maximal 9.7 ± 1.7-fold increase in contractile force at a concentration of 100 nM with an EC~50~ of 21 nM ([Figure 3C](#kfz168-F3){ref-type="fig"}, [Supplemental Table 2](#sup1){ref-type="supplementary-material"}). Digoxin at concentration of 1 µM induced ectopic activity and significantly prolonged the duration of contraction ([Supplemental Figure 1](#sup1){ref-type="supplementary-material"}). At concentrations above 10 μM, ECT contractility was significantly diminished and contraction could not be elicited in the majority of the ECTs using external field stimulation.

Thapsigargin, a noncompetitive inhibitor of SERCA activity reduces the SR calcium load and leads to increased cytosolic calcium and reduced contractility. Treatment of ECTs with thapsigargin completely inhibited contraction at concentrations above 1 μM with IC~50~ of 165 nM ([Figure 3D](#kfz168-F3){ref-type="fig"}, [Supplemental Table 2](#sup1){ref-type="supplementary-material"}).

### ECTs Respond to Sarcomere Modulators

In the cardiac sarcomere, energy derived from myosin-mediated ATP hydrolysis is used to drive contraction ([@kfz168-B24]). Omecamtiv mecarbil (OM) is a novel positive inotrope that binds to and stimulates the ATPase activity of myosin resulting in an increased force of contraction in humans ([@kfz168-B33]). Treatment of ECTs with OM elicited a maximal 2.6 ± 0.3-fold increase in contractile force at a concentration of 10 µM with an EC~50~ of 370 nM ([Figure 4A](#kfz168-F4){ref-type="fig"}). OM at 10 μM significantly increased the time of contraction and relaxation and had no effect on the rates of contraction and relaxation ([Supplemental Table 3](#sup1){ref-type="supplementary-material"}). In contrast, treatment of ECTs with MYK-461 (mavacamten), an inhibitor of cardiac myosin ATPase, completely abolished contraction at concentrations above 10 μM with IC~50~ of 287 nM ([Figure 4B](#kfz168-F4){ref-type="fig"}, [Supplemental Table 3](#sup1){ref-type="supplementary-material"}).

![Engineered cardiac tissues (ECTs) display canonical inotropic responses to sarcomere modulators and activation of phospholipase C. A, Omecamtiv increased the contractile force with EC~50~ of 370 nM (*n* = 9). B, Conversely, increasing doses of MYK461 decreased the contractile force with IC~50~ of 287 nM (*n* = 6). C, Treatment with levosimendan increased the contractile force (*n* = 9) with EC~50~ of 234 nM. D, Treatment with endothelin-1 which stimulates the activity of phospholipase C (PLC), increased the contractile force with EC~50~ of 98 pM (*n* = 6). Data are presented as mean ± SEM.](kfz168f4){#kfz168-F4}

Cardiac troponin is a trimeric protein complex in the sarcomere ([@kfz168-B43]). It plays a critical role in regulating sensitivity to Ca^2+^. Levosimendan is a positive inotrope that modulates troponin-C, 1 protein of the trimer and increases its sensitivity to regulation by Ca^2+^ ([@kfz168-B34]; [@kfz168-B38]). Treatment of ECTs with levosimendan induced a maximal 3.3 ± 0.4-fold increase in contractile force at a concentration of 2 μM with an EC~50~ of 234 nM ([Figure 4C](#kfz168-F4){ref-type="fig"}).

### ECTs Respond to Activation of Phospholipase C

Endothelin-1 (ET-1) is a 21-amino acid peptide that binds to the ET receptor, a G~q~-protein-coupled receptor, and activates phospholipase C ([@kfz168-B45]). Second messenger effects are proposed to mediate positive inotropic events that involve modulation of the intracellular Ca^2+^ transients and myofilament Ca^2+^ sensitivity. Treatment of ECTs with ET-1 induced a maximal 5.2 ± 0.7-fold increase in contractile force at 40 nM with an EC~50~ of 98pM ([Figure 4D](#kfz168-F4){ref-type="fig"}, [Supplemental Table 3](#sup1){ref-type="supplementary-material"}).

DISCUSSION
==========

Here we evaluated the contractile function of human 3D ECTs generated from hiPSC-CMs in the Biowire II platform. We demonstrate that the platform enables the generation of 3D ECTs that remain viable and retain their functionality for weeks. These ECTs develop properties of the adult myocardium and exhibit robust responses to a variety of inotropic compounds with distinct mechanisms of action selected to confirm the presence, and interrogate the function of, pathways known to regulate cardiac function.

G-protein coupled receptor signaling pathways play a critical role in functional adaptation in the heart by regulating inotropic and chronotropic responses. Endothelin-1, a potent vasoactive peptide signaling via the phospholipase-C/protein kinase-C pathway, has been shown to regulate cardiac contractility both *in vivo* and in isolated human myocardium ([@kfz168-B23]; [@kfz168-B31]). ECTs generated a positive inotropic response, in a concentration-dependent manner, upon exposure to ET-1; confirming the presence of a functional ET-1 receptor signaling cascade. In patients suffering from HF, dysregulation of β-adrenergic signaling is a common feature of cardiac pathophysiologies and a target of therapy eg, β-adrenergic antagonists are a cornerstone of therapy ([@kfz168-B7]). We demonstrated canonical responses to the well-studied β-agonists isoproterenol and dobutamine. Inotropic responses are observed for PACAP27, which activates adenylyl cyclase via receptors distinct from isoproterenol and milrinone (an inhibitor of cAMP degradation) indicating that a range of cAMP-mediated signaling cascades are also present in the ECTs. Although observation of the stimulatory effects of β-adrenergic agonism in engineered human heart tissues is not novel, previous reports have suggested little to no significant effect on contractility ([@kfz168-B19]), but rather an increase in chronotropy. Additionally, others have observed positive inotropic responses at concentrations far right-shifted and therefore, less physiologically relevant to effects observed in the in this study ([@kfz168-B51]). Interestingly, milrinone has been shown to produce a positive inotropic response in fibroblast containing ECTs ([@kfz168-B37]), whereas when tissues were prepared without fibroblasts, there was no inotropic response to milrinone as compared to human heart tissue ([@kfz168-B25]); suggesting maturity in the adrenergic pathway and/or enhanced PDE3A expression in fibroblast containing ECTs. We observed a significant increase in the magnitude of force generated in response to milrinone in ECTs electrically stimulated for 6 weeks as compared to 3 weeks, demonstrating that long term electrical stimulation is also an important factor that contributes to the increased inotropic response to milrinone ([Supplemental Figure 2](#sup1){ref-type="supplementary-material"}). Further studies are required to determine the mechanism by which the inotropic response to milrinone was increased in ECTs generated in the Biowire II platform.

Calcium channels are both the direct and indirect target of various cardiac therapies. LTCC antagonists are a mainstay in the treatment of hypertension, cardiac ischemia, and arrhythmias, but can elicit cardio depressant effect. Conversely, compounds such as Bay K-8644 and the more potent FPL 64176 were designed to stimulate LTCC activity and have the consequent effect of increasing the contractile force. As such, treatment of the ECTs with the LTCC blocker, nifedipine and with FPL 64176 yielded the expected result of decreased and increased contractility respectively, indicating the LTCC of the ECT was functional and could be regulated by external stimuli. One of the oldest HF therapies is digoxin, a cardiac glycoside isolated from the foxglove plant. Digoxin induces a positive inotropic effect via its ability to promote Ca^2+^ loading in the SR. A biphasic increase in force was observed when ECTs were treated with digoxin at or below 1 μM demonstrating that contractility can be regulated at the level of NCX and that the SR modulates Ca^2+^ levels in a physiologically relevant manner. Treatment of tissues with digoxin at concentrations above 1 μM showed toxic effects commonly observed with this compound ([Supplemental Figure 1](#sup1){ref-type="supplementary-material"}) ([@kfz168-B25]; [@kfz168-B39]).

The recent discovery of agents that modulate sarcomere proteins holds great promise for the development of novel treatments for HF. OM is an agent that directly regulates cardiac myosin and levosimendan is an agent that regulates the function of troponin-C, the Ca^2+^ sensor of the sarcomere. Data from studies in HF patients show OM and levosimendan can promote a positive inotropic effect and hemodynamic improvements ([@kfz168-B14]; [@kfz168-B47]) without a significant increase in oxygen consumption ([@kfz168-B22]; [@kfz168-B41]; [@kfz168-B48]). Consistent with data from clinical and animal studies, both compounds were able to modulate contractility in ECTs eliciting significant increases in contractile force with concentrations typical for these compounds ([@kfz168-B27]). MYK461, a small molecule inhibitor of myosin also shows potential in the treatment of HF. Tissue treated with MYK461 showed significant decrease in contractility in the range consistent with published results ([@kfz168-B15]).

In conclusion, human ECTs created in the Biowire II platform have adult-like canonical responses to compounds known to affect contractility via an array of physiologically relevant pathways ([Figure 5](#kfz168-F5){ref-type="fig"}, Summary data presented in [Table 1](#kfz168-T1){ref-type="table"}). These studies can be conducted under external stimulation, providing investigators with a high degree of experimental control, and with the ability to assess compounds using a nondestructive measurement of contractility. This model can be used to assess the effects of novel compounds in a human-based model of contractility early in the drug discovery and development process. These results suggest the utility of the Biowire II platform to create disease models via the use of patient derived iPSC-CMs.

###### 

Summary of Engineered Cardiac Tissues (ECT) Inotropic Responses

  Compound        ECT EC~50~/IC~50~   Effective Plasma Concentration or EC~50~/IC~50~   Reference
  --------------- ------------------- ------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Isoproterenol   0.5 nM              27 nM^a^                                          EC~50~ in isolated human ventricular muscle strip ([@kfz168-B13])
  Dobutamine      16 nM               133--632 nM                                       Plasma levels of 133 nM were associated with significant increase in cardiac index with linear increase in index up to 632 nM ([@kfz168-B21])
  Milrinone       1.6 µM              0.791 µM                                          Plasma concentration associated with 50% increase in cardiac index ([@kfz168-B2])
  PACAP27         1.1 nM              0.5 nM^a^                                         Recalculated EC~50~ in dog isolated left ventricle ([@kfz168-B18])
  Nifedipine      62 nM               10--81 nM                                         Steady state of 10 nM ([@kfz168-B35]), plasma levels above 81 nM were associated with decreased d*p*/d*t*~max~ ([@kfz168-B9])
  FPL64176        502 nM              600 nM^a^                                         Recalculated EC~50~ in guinea pig papillary muscle ([@kfz168-B36])
  Digoxin         21 nM               1.5--2.6 nM                                       Plasma level range in patients with improved fractional shortening ([@kfz168-B17])
  Thapsigargin    165 nM              300 nM^a^                                         Complete inhibition of contraction in isolated adult rat cardiomyocytes ([@kfz168-B50])
  Omecamtiv       370 nM              792 nM                                            Maximum plasma level associated with increased stroke volume ([@kfz168-B46])
  MYK461          287 nM              180 nM^a^                                         IC~50~ in adult rat ventricular cardiomyocytes ([@kfz168-B15])
  Levosimendan    234 nM              351 nM                                            Plasma level associated with increased stroke volume ([@kfz168-B20])
  Endothelin-1    0.1 nM              9.1 nM^a^                                         EC~50~ in isolated human ventricular trabeculae ([@kfz168-B40])

The EC~50~/IC~50~ for each compound was compared to the effective therapeutic dose of the compound where data were available. For compounds where effective therapeutic dose was not available, comparison was made with published results from *in vitro* or animal models and is indicated by superscript letter (a).

![Engineered cardiac tissues (ECTs) generated in Biowire II platform have canonical responses to compounds that affect contractility via physiologically relevant pathways. A, β-adrenergic/cAMP-mediated pathway and the L-type calcium channel. β-AR, β-adrenergic receptor; AC, adenylyl cyclase; PACAP, pituitary adenylate cyclase-activating peptide; cAMP, cyclic adenosine monophosphate; ATP, adenosine triphosphate; PDE, phosphodiesterase; PKA, protein kinase A; RYR2, ryanodine receptor; TnI, troponin-I; PLB, phospholamban. B, G~q~-protein-coupled receptor signaling. ET-R, endothelin receptor; PLC, phospholipase C; PIP~2~, phosphatidylinositol 4, 5-bisphosphate; IP~3~, inositol 1, 4, 5-trisphosphate; DAG, diacylglycerol; PKC, protein kinase C. C, Modulation of proteins of the cardiac sarcomere.](kfz168f5){#kfz168-F5}
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